Zimmer Biomet CEO Says Says Excluding Impact Of China Distributor Network Consolidation, Q3 Constant-Currency Sales Growth Would Have Been 4.4%; Global Knees Sales Would Have Been Flat YoY In Q3 Excluding China Headwinds; Expects To File Monogram 510(K) Application With FDA Very Soon, Ahead Of Schedule; China-Related Headwinds Will Anniversary In January 2027, Improving Visibility Into Knees Performance
-Conference Call.
Share
Why It Matters
Zimmer Biomet had slower sales growth because of China business changes. When you look at this company, watch if their knee sales improve once China issues go away in early 2027.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.